NCT00250822View on ClinicalTrials.gov

Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Liver Cancer
Interventions
DRUG

Gemcitabine and Oxaliplatin

"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 \& 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 \& 16"

Trial Locations (4)

87108

Lovelace Sandia Health Systems Dept of Hematology, Albuquerque

87131

University of New Mexico, Albuquerque

87505

St. Vincent Regional Medical Center, Santa Fe

87102-3661

Hematology Oncology Associates, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT00250822 - Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter | Biotech Hunter | Biotech Hunter